Pharma BD Deal Intelligence

Mylan N.V. / Meda AB

2016 · Acquisition/Merger · $9.9B · Complete

Announcement Sentiment

Positive

Outcome Score

Mixed — partial payoff, real shortfalls.

Mylan acquired Meda for $9.9B to expand branded and generic drug portfolio.

Key facts

Announced Feb 10, 2016
Closed Aug 05, 2016
Deal value $9.9B
Deal type Acquisition/Merger
Key assets azelastine/fluticasone propionate (Dymista), Branded generics / specialty portfolio